Study on the Effects of Dexmedetomidine on Neuroinflammation in COVID-19 ARDS Survivors

This clinical trial is focused on patients who have survived a severe lung condition known as Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. After being treated in intensive care, many of these patients experience a condition called delirium, which can lead to long-term brain inflammation and affect memory and thinking abilities. The study is investigating whether a medication called dexmedetomidine, which is used for sedation, can help reduce this brain inflammation and improve recovery.

The trial will involve two groups of patients: those who receive dexmedetomidine and those who do not. The medication will be given through an injection into a vein. Researchers will use a special imaging technique called PET-MRI to look at the brain and measure inflammation levels. This will be done 24 months after the patients have been discharged from intensive care. The study aims to see if dexmedetomidine can help protect the brain and improve cognitive function, which includes memory and thinking skills.

Another part of the study will look at how dexmedetomidine affects brain health by using brain scans and clinical assessments. Researchers will also explore biological factors that might influence brain inflammation after severe COVID-19 infection. The goal is to better understand how to manage brain health in patients recovering from COVID-19-related ARDS and to identify any risk factors that might contribute to long-term brain inflammation.